We read with great interest the recent manuscript on treatment of primary central nervous system lymphoma (PCNSL) with highdose chemotherapy followed by autologous hematopoietic SCT. 1 The authors highlight several important issues regarding the difficulties with treating this disease. Indeed, a recent review of clinical experience with PCNSL concluded that high-dose chemotherapy ± whole-brain radiotherapy followed by autologous HSCT holds promise to improve patient outcomes.
1
The authors highlight several important issues regarding the difficulties with treating this disease. Indeed, a recent review of clinical experience with PCNSL concluded that high-dose chemotherapy ± whole-brain radiotherapy followed by autologous HSCT holds promise to improve patient outcomes. 2 Although this latest review of PCNSL is thought-provoking, we find discrepancies that may confound the authors' conclusions.
As acknowledged by the authors, there is a great heterogeneity of both induction and conditioning regimens employed in studies for newly-diagnosed PCNSL. 2 Bearing in mind not only the variations in chemotherapy regimens, but also the variations of survival seen in these studies, we are surprised to find the authors' conclusion of superiority with 'thiotepa/busulfan based conditioning' and recommendation of this strategy as a 'suggested treatment approach in patients with PCNSL'. 1 Although these two agents may have a role in conditioning for autologous HSCT to treat newly-diagnosed PCNSL, the scarcity of data makes their role ill-defined. 2 The majority of conditioning regimens employed in studies on newly-diagnosed PCNSL do not contain thiotepa and fewer still contain BU. 2 The total number of patients with newlydiagnosed PCNSL who had received a BU and thiotepa-based conditioning regimen before autologous HSCT was 53, a number far too small to use as the basis for an algorithm for the treatment of newly-diagnosed PCNSL patients. 3, 4, 5 Additionally, we express our trepidation regarding the authors' preferred multi-agent conditioning regimen of thiotepa, etoposide, cytarabine, and melphalan (TEAM). The only agent in this regimen that has appreciable blood --brain barrier penetration at the doses referenced is thiotepa, even in patients with impaired blood --brain barrier due to PCNSL. 6 Minimal improvements in survival were seen when using BEAM as a conditioning regimen for newly-diagnosed PCNSL following a high-dose MTX-based induction regimen, a finding attributed to lack of dose intensity in the central nervous system from etoposide, cytarabine and melphalan. 2, 6 Clearly, TEAM is a variation of BEAM, with the primary differences being replacement of carmustine with thiotepa and modification to etoposide and/or cytarabine doses, depending on the comparator BEAM regimen. 7, 8 Indeed, at the doses employed, carmustine penetrates the blood --brain barrier into the central nervous system most avidly in the four-drug BEAM regimen. 6 However, the replacement of carmustine with thiotepa resulted from concerns over pulmonary toxicity and not out of any benefit in blood brain barrier penetration with thiotepa. 9 It stands to reason that similar outcomes would be expected with the use of TEAM compared with those, which have historically been seen with BEAM. Inexplicably, the authors' preference given to the TEAM conditioning regimen is later contradicted by postulating an algorithm for PCNSL using a BU/thiotepa-based conditioning regimen. 1 The present application of BU in HSCT-conditioning regimens requires therapeutic drug monitoring to attain a target area-under-the-curve. 10 Currently available data do not clearly elucidate a target serum area-under-the-curve to optimally treat PCNSL while avoiding undue adverse effects such as hepatic venoocclusive disease. Additionally, the combination of thiotepa and BU was associated with greater treatment-related mortality when compared with the BEAM regimen in a multicenter trial. 3 The authors recommend a high-dose MTX-based induction regimen, which is appropriate in some patients. MTX has greater utility in younger patients with excellent performance status, although PCNSL is a disease of the elderly whose comorbidities create a barrier to the administration of this highly effective agent. In clinical practice, careful consideration must be given to patientspecific comorbidities, performance status and prior treatment (if any). In the two largest trials, only 50 --77% of patients enrolled progressed through induction to receive autologous HSCT, with many patients dropping out due to toxicity.
